Amneal inks licensing deal for levothyroxine
Amneal Pharmaceuticals has reached a 10-year license and supply agreement with Jerome Stevens Pharmaceuticals for levothyroxine sodium tablets.
Levothyroxine sodium tablets are used in the therapeutic areas of hypothyroidism and pituitary TSH suppression.
"Levothyroxine is one of the most compelling generic product markets in the United States today," Rob Stewart, president and CEO of Amneal, said. "With more than 120 million prescriptions per year, levothyroxine is the most prescribed drug in the United States, and we see exciting opportunities to grow market share, given the evolving market dynamics in the space and the manufacturing and validation challenges associated with this product. Moreover, this agreement strengthens our long-term relationship with JSP, which has consistently manufactured levothyroxine to a high-quality specification for more than 25 years."
The agreement includes an upfront milestone payment upon commercialization and a profit share on future sales of Levothyroxine. Further terms of the agreement were not disclosed.
The market value for levothyroxine sodium tablets is estimated to be approximately $2.6 billion in annual sales and 122 million annual prescriptions for the 12 months ended June 2018, according to IQVIA.
Levothyroxine sodium tablets are used in the therapeutic areas of hypothyroidism and pituitary TSH suppression.
"Levothyroxine is one of the most compelling generic product markets in the United States today," Rob Stewart, president and CEO of Amneal, said. "With more than 120 million prescriptions per year, levothyroxine is the most prescribed drug in the United States, and we see exciting opportunities to grow market share, given the evolving market dynamics in the space and the manufacturing and validation challenges associated with this product. Moreover, this agreement strengthens our long-term relationship with JSP, which has consistently manufactured levothyroxine to a high-quality specification for more than 25 years."
The agreement includes an upfront milestone payment upon commercialization and a profit share on future sales of Levothyroxine. Further terms of the agreement were not disclosed.
The market value for levothyroxine sodium tablets is estimated to be approximately $2.6 billion in annual sales and 122 million annual prescriptions for the 12 months ended June 2018, according to IQVIA.